Journal of Chemotherapy · 2015 · 19 citations · 7 references
MedicineAudiologyOncologyChemotherapyHearing AssessmentOtologyAdverse Effects Of ChemotherapyChemotherapy Toxicity ManagementHearing ImpairmentHearing LossOtotoxicityToxicity ManagementAudiometric AbnormalitiesChemotherapy-induced OtotoxicityChemotherapy-related OtotoxicityCochlear ToxicityDrug-induced Hearing LossPharmacologic OtotoxicityPlatinum-based AgentsPlatinum-based Ototoxicity
Oxaliplatin is used to treat advanced colorectal cancer. Platinum-containing chemotherapeutic agents are known to be ototoxic. However, ototoxicity is rare with newer generation platinum-derived agents, such as oxaliplatin. This case report presents a rare case of sudden unilateral sensorineural hearing loss following intravenous (IV) infusion of oxaliplatin in a 64-year-old woman with advanced colon cancer. The hearing loss was severe and did not respond to treatment. To the best of our knowledge, this is the fifth reported case of oxaliplatin ototoxicity. Although oxaliplatin ototoxicity is rare, physicians must be aware of this important adverse effect, and an audiometric evaluation must be performed when necessary. Patients treated with oxaliplatin should be followed closely for early signs and symptoms of hearing loss, and if hearing loss is detected, treatment should be stopped immediately.
7
Robert J. Stachler, Sujana S. Chandrasekhar, Sanford M. Archer et al. · Otolaryngology · 2012 · 950 citations
Medicine, Otolaryngology, Surgery +15
Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.
Roger R. Reddel, Richard Kefford, Justin Grant et al. · PubMed · 1982 · 188 citations
Medicine, Audiology, Otolaryngology +16
FDA Drug Approval Summaries: Oxaliplatin
Amna Ibrahim, Steven Hirschfeld, Martin H. Cohen et al. · The Oncologist · 2004 · 174 citations · Full text
Medicine, Oncology, Pharmacology +17